Gilead Sciences, Inc. (NASDAQ:GILD) Insider Sells $3,318,840.00 in Stock

Key Points

• Insider Johanna Mercier of Gilead Sciences sold 28,000 shares for approximately $3.32 million, decreasing her position by 19.7% and owning 114,168 shares post-transaction.
• Gilead's stock is currently down 0.3% at $117.99, with a market capitalization of $146.40 billion and a price-to-earnings ratio of 23.50.
• The company reported earnings of $2.01 per share for the last quarter, exceeding expectations, with a revenue of $7.08 billion, up 1.4% year-over-year.

Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) insider Johanna Mercier sold 28,000 shares of the company's stock in a transaction on Friday, August 15th. The shares were sold at an average price of $118.53, for a total value of $3,318,840.00. Following the completion of the transaction, the insider directly owned 114,168 shares in the company, valued at approximately $13,532,333.04. This trade represents a 19.70% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Johanna Mercier also recently made the following trade(s):

• On Tuesday, July 15th, Johanna Mercier sold 3,000 shares of Gilead Sciences stock. The shares were sold at an average price of $111.03, for a total value of $333,090.00.
• On Tuesday, July 15th, Johanna Mercier sold 3,000 shares of Gilead Sciences stock. The shares were sold at an average price of $111.03, for a total value of $333,090.00.
• On Monday, June 16th, Johanna Mercier sold 3,000 shares of Gilead Sciences stock. The shares were sold at an average price of $110.17, for a total value of $330,510.00.
• On Thursday, May 22nd, Johanna Mercier sold 28,000 shares of Gilead Sciences stock. The shares were sold at an average price of $107.52, for a total value of $3,010,560.00.

Gilead Sciences Stock Down 0.3%

NASDAQ GILD traded down $0.38 during trading hours on Monday, hitting $117.99. 4,474,821 shares of the company were exchanged, compared to its average volume of 6,512,909. The company has a 50 day moving average of $111.98 and a two-hundred day moving average of $108.64. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a 52-week low of $73.27 and a 52-week high of $121.83. The firm has a market cap of $146.40 billion, a price-to-earnings ratio of 23.50, a PEG ratio of 0.73 and a beta of 0.33.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%. The company had revenue of $7.08 billion for the quarter, compared to the consensus estimate of $6.95 billion. During the same quarter in the prior year, the business earned $2.01 EPS. Gilead Sciences's revenue was up 1.4% on a year-over-year basis. Equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, September 29th. Stockholders of record on Monday, September 15th will be issued a $0.79 dividend. The ex-dividend date is Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.7%. Gilead Sciences's dividend payout ratio is presently 62.95%.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in GILD. Norges Bank purchased a new position in shares of Gilead Sciences in the 2nd quarter valued at about $2,150,268,000. Price T Rowe Associates Inc. MD increased its holdings in shares of Gilead Sciences by 314.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company's stock valued at $1,647,484,000 after acquiring an additional 11,156,382 shares during the last quarter. Nuveen LLC purchased a new position in shares of Gilead Sciences in the 1st quarter valued at about $620,415,000. Ameriprise Financial Inc. increased its holdings in shares of Gilead Sciences by 397.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 6,748,403 shares of the biopharmaceutical company's stock valued at $748,147,000 after acquiring an additional 5,392,191 shares during the last quarter. Finally, Invesco Ltd. increased its holdings in shares of Gilead Sciences by 33.5% in the 2nd quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company's stock valued at $1,499,098,000 after acquiring an additional 3,394,330 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company's stock.

Analyst Ratings Changes

Several brokerages have recently commented on GILD. Needham & Company LLC raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price target on the stock in a research note on Friday, July 25th. Cantor Fitzgerald initiated coverage on Gilead Sciences in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price target on the stock. Royal Bank Of Canada increased their target price on Gilead Sciences from $96.00 to $98.00 and gave the stock a "sector perform" rating in a research note on Friday, August 8th. Truist Financial raised Gilead Sciences from a "hold" rating to a "buy" rating and increased their target price for the stock from $108.00 to $127.00 in a research note on Friday, August 8th. Finally, Oppenheimer decreased their target price on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research note on Friday, April 25th. Seven analysts have rated the stock with a hold rating, sixteen have given a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $114.82.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.